<DOC>
	<DOCNO>NCT01744496</DOCNO>
	<brief_summary>This trial conduct compare impact Rotigotine Placebo Chronic Pain associate Parkinson 's Disease among patient advanced stage disease .</brief_summary>
	<brief_title>Study Evaluate Efficacy Rotigotine Parkinson 's Disease-Associated Pain</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Patient advance idiopathic Parkinson 's Disease associate chronic pain assess Likert Pain Scale Patient take Levodopa stable daily dose least 200 mg least 21 day prior start Hoehn Yahr stage score II IV MiniMental State Examination ( MMSE ) score â‰¥ 25 If antidepressant drug take , dose must stable least 21 day Therapy Dopamine Agonist within 21 day prior start Discontinuation previous Dopamine Agonist Therapy due lack efficacy Therapy Dopaminemodulating substance 21 day prior start Therapy analgesic treatment pain , unless dose stable Chronic alcohol drug abuse Medical psychiatric condition , opinion investigator , could jeopardize would compromise patient 's ability participate study Hypersensitivity components Investigational Medicinal Product ( IMP ) comparative drug Atypical Parkinson 's Disease Syndrome due drug History deep brain stimulation Significant skin disease would make transdermal drug use inappropriate Electroconvulsive therapy within 12 week prior start Evidence Impulse Control Disorder Previous diagnosis severe Restless Legs Syndrome Chronic Migraine Severe Depression Symptomatic Orthostatic Hypotension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Rotigotine</keyword>
	<keyword>Chronic Pain</keyword>
	<keyword>Nonmotor symptom</keyword>
</DOC>